After decades of relying on daily pills, England and Wales just approved something different for HIV prevention—a jab that works for two months at a time.
A game-changing two-month HIV prevention injection just got NHS approval, ditching the daily pill routine entirely.
Injectable cabotegravir, or CAB-LA, just became the first HIV prevention injection widely available through the NHS. This isn’t just another treatment option. It’s a complete shift in how people can protect themselves from HIV.
The drug is an integrase strand transfer inhibitor. Big words, simple concept: it blocks HIV from integrating into human DNA. The virus can’t enter cells, can’t multiply, can’t establish infection. Game over for HIV before it even starts.
Here’s where it gets interesting. CAB-LA reduced HIV infection risk by about 79% more than oral daily PrEP in clinical trials. That’s not a typo. Daily pills, when taken correctly, already reduce sexual transmission risk by about 99%. This injection just makes that protection even more bulletproof.
The injection schedule is straightforward—every two months after initial loading doses. No daily pill reminders. No carrying medication. No awkward moments at pharmacy counters. Protection starts about a week after the first shot.
Clinical trials showed effectiveness across diverse groups: cisgender men, cisgender women, transgender women who have sex with men. The common thread? All were at higher risk of HIV through sexual exposure. Remote monitoring technologies help healthcare providers track patient adherence and outcomes more effectively.
Side effects are mostly mild. Injection site pain tops the list. Some people get headaches or fever, but these typically resolve quickly. Nothing catastrophic emerged from trials.
The approval targets England and Wales specifically, expanding beyond oral PrEP options for people at higher HIV risk. NHS England has ambitious goals—reducing new HIV transmissions to zero by 2030. This injection might actually help achieve that target.
There’s one major caveat. The injection’s effectiveness for people exposed through injection drug use hasn’t been confirmed. Sexual exposure? Covered. Needle sharing? Different story.
The real advantage isn’t just medical—it’s practical. Daily pills require perfect adherence. Miss doses, lose protection. This injection eliminates that daily decision entirely. Better adherence means better protection. Meanwhile, a new twice-yearly injection called Yeztugo has recently gained FDA approval, offering even longer protection intervals. The medication targets the roughly 1.2 million persons in the United States who have medical indications for HIV prevention therapy. Sometimes the simplest solutions work best.
